These analyses aim to identify therapeutic strategies for melanoma by targeting key genes (AHR, MAP2K1, KLF5, PRKACB, PIK3R2) and their regulatory RNA networks, offering potential for personalized treatments and novel biomarkers to improve clinical outcomes. This evidence concerns the gene MAP2K1 and melanoma.